Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
137results about "Carbon-sulfur lyases" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith
ActiveUS9200251B1Good treatment effectProphylaxis or treatment of neoplastic diseasesBiocideOrganic active ingredientsHyperhomocystinemiaAntifungal
A substantially purified substance having the properties of a bacterial microcin methionine analog, methionine synthesis inhibitor, tRNA-methionine synthase inhibitors or methionine competitive inhibitor capable of inhibiting tumor cell growth without inhibiting the growth of normal cells or treating neoplastic diseases, and may be used alone or in combination with other anti-cancer agents. The purified substance may also have anti-hyperhomocysteineuria and / or anti-infective properties, such as antifungal activity. The purified substance can be safely administered to animals including humans for the treatment of neoplastic, hyperhomocysteinemia and / or infectious diseases for the treatment of those diseases.
Owner:BERMUDES DAVID GORDON
Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
ActiveUS20110200576A1Low immunogenicityIncrease serum stabilityBacteriaPeptide/protein ingredientsAmino acid substitutionLyase
Methods and composition related to the engineering of a novel protein with methionine-γ-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase (CGL) comprising one or more amino acid substitutions and capable of degrading methionine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with methionine depletion using the disclosed proteins or nucleic acids.
Owner:AEMASE
Recombinant production systems for prenylated polyketides of the cannabinoid family
The present invention relates generally to production methods, enzymes and recombinant yeast strains for the biosynthesis of clinically important prenylated polyketides of the cannabinoid family. Using readily available starting materials, heterologous enzymes are used to direct cannabinoid biosynthesis in yeast.
Owner:BAYMEDICA INC
Application of genetically engineered bacterium VNP-20009-M in preparation of medicines for preventing and treating cancer metastasis
PendingCN105983103AInhibit transferHas antitumor effectCarbon-sulfur lyasesBacteriaTumor targetCancer cell
The invention discloses application of genetically engineered bacterium VNP-20009-M of attenuated salmonella typhimurium in preparation of medicines for preventing and treating metastasized cancers. The genetically engineered bacterium VNP20009-M has a tumor targeting property on cancer cells, has a remarkable effect for inhibiting metastasis and growth of cancer cells, and can be used for preparing medicines for preventing and treating metastasized tumors.
Owner:GUANGZHOU SINOGEN PHARMA CO LTD
Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
ActiveUS8709407B2Low immunogenicityIncrease serum stabilityCarbon-sulfur lyasesSugar derivativesAmino acid substitutionLyase
Owner:AEMASE
Methods for dissolving cystine stones and reducing cystine in urine
The present invention is directed to an improved method of treating cystinuria, utilizing the catalytic ability of cystinase to increase the rate of cystine stone dissolution.
Owner:CODEXIS INC
Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith
ActiveUS9365625B1Good treatment effectProphylaxis or treatment of neoplastic diseasesOrganic active ingredientsBiocideBacteroidesAnticarcinogen
A substantially purified substance having the properties of a bacterial microcin methionine analog, methionine synthesis inhibitor, tRNA-methionine synthase inhibitors or methionine competitive inhibitor capable of inhibiting tumor cell growth without inhibiting the growth of normal cells or treating neoplastic diseases, and may be used alone or in combination with other anti-cancer agents. The purified substance may also have anti-hyperhomocysteineuria and / or anti-infective properties, such as antifungal activity. The purified substance can be safely administered to animals including humans for the treatment of neoplastic, hyperhomocysteinemia and / or infectious diseases for the treatment of those diseases.
Owner:BERMUDES DAVID GORDON
Engineered primate L-methioninase for therapeutic purposes
ActiveUS9481877B2Low immunogenicityIncrease serum stabilityFungiCarbon-sulfur lyasesPrimateAmino acid substitution
Methods and compositions relating to the engineering of an improved protein with methionine-γ-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase (CGL) comprising one or more amino acid substitutions and capable of degrading methionine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with methionine depletion using the disclosed proteins or nucleic acids.
Owner:BOARD OF REGENTS
Production of cannabinoids in yeast
The present disclosure relates to the production of cannabinoids in yeast. In one aspect there is provided a genetically modified yeast comprising: one or more GPP producing genes and optionally, oneor more GPP pathway genes; two or more olivetolic acid producing genes; one or more cannabinoid precursor or cannabinoid producing genes; one or more Hexanoyl-CoA producing genes, and at least 5% dryweight of fatty acids or fats.
Owner:BIOMEDICINES INC
Engineered primate cystine/cysteine degrading enzymes as antineogenic agents
ActiveUS20150064160A1Low KMHigh catalytic activityBacteriaPeptide/protein ingredientsCysteine degradationPrimate
Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with L-cyst(e)ine using the disclosed proteins or nucleic acids.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Preparation method and low-temperature continuous stirring ultrafiltration device for anti-tumor and anti-infection allicin injection
ActiveCN102058527AReduce decompositionAntibacterial agentsOrganic active ingredientsDiseaseUltrafiltration
The invention discloses a preparation method and low-temperature continuous stirring ultrafiltration device for an anti-tumor and anti-infection allicin injection. The preparation method for the anti-tumor and anti-infection allicin comprises the following two steps: 1. extracting allicin; 2. in a clean environment, diluting the allicin extracted in the step 1 by utilizing a dissolvent precooled to 0-4 DEG C to obtain an allicin solution; and packaging the allicin into allicin injections of different specifications according to ampoule required to fill nitrogen or argon. The anti-tumor and anti-infection allicin injection can be used for intravenous drip to treat diseases such as sepsis or tumor and the like. The invention simultaneously discloses a low-temperature continuous stirring ultrafiltration device for preparing the allicin injection. The invention has the advantages that the formula is reasonable, and the preparation technology is simple; the defects of the prior art are overcome; and the product purity is high, and the performance is stable.
Owner:新疆胡蒜研究院(有限公司)
Novel high-activity allinase and preparation method thereof
ActiveCN105838729AIncreased specific enzyme activityEasy to produceCarbon-sulfur lyasesFermentationSurface displayBiotechnology
The invention relates to a novel high-activity allinase and a preparation method thereof. The preparation method is characterized in that a wild type allinase gene from a garlic bulb is transformed by utilizing a random mutation technology, and a high-activity allinase mutant gene, namely a novel high-activity allinase gene, is obtained; then the novel high-activity allinase gene is expressed in a bacillus subtilis expression system and pichia pastoris expression systems (including a pichia pastoris free expression system and a pichia pastoris cell surface display system) respectively, and recombination strains for producing the high-activity allinase are obtained; detections carried out after fermentation expression show that the specific enzyme activity of the novel high-activity allinase is improved by 50% in comparison with a wild type allinase.
Owner:TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY
Method for purifying alliinase by double-water-phase separation
The invention belongs to the field of deep processing of garlic, and particularly discloses a method for purifying alliinase by double-water-phase separation. The method comprises the following steps: (1) peeling and precooling garlic squamous bulbs, immersing in a precooled extract, homogenizing, centrifuging, and discarding garlic slag, thereby obtaining the supernate crude enzyme solution; (2) dissolving ammonium sulfate, sodium dihydrogen phosphate or trisodium citrate in a Britton-Robinson buffer solution, oscillating to completely dissolve, adding a PEG (polyethylene glycol) solution, evenly mixing by oscillation, and standing for phase splitting, thereby obtaining a double-water-phase extractant; (3) adding the crude enzyme solution into the double-water-phase extractant, oscillating, centrifuging, and standing for phase splitting; and (4) ultrafiltering the lower phase of the enriched alliinase, and carrying out vacuum freeze drying on the trapped fluid to obtain the alliinase solid. The method is simple to operate, has the advantages of simple apparatuses, time saving, low cost, and higher alliinase purification multiple and enzyme activity recovery rate than the prior art, and can easily implement scale-up production.
Owner:QILU UNIV OF TECH
Genetically engineered bacterium for treatment of breast cancer, method for constructing the bacterium, and applications thereof
ActiveUS20150376593A1Good antitumor activitySimple methodBiocidePeptide/protein ingredientsEngineered geneticGenetically engineered
The current invention discloses a genetically engineered bacterium used for the treatment of breast cancer. The said bacterium is attenuated Salmonella typhimurium VNP20009 with cloned L-methioninase gene. The method for constructing this genetically engineered bacterium and the application thereof are also disclosed herein. In the current invention, our biologic drug for the treatment of breast cancer is a type of safe, non-toxic new drug with anti-tumor activity. It can highly express methioninase through recombinant DNA technology using attenuated Salmonella typhimurium VNP20009 as a carrier, which has a strong anti-tumor activity and can meet the needs. The preparation method is simple and easy to operate, showing good application prospect.
Owner:GUANGZHOU SINOGEN PHARMA CO LTD
Avian pathogenic escherichia coli strain and application thereof in vaccine preparation
The invention belongs to the field of biotechnology, and provides an avian pathogenic escherichia coli strain, which is an avian pathogenic escherichia coli luxS and aroA double-gene-deleted strain with the preservation numbr of CGMCC10601. The avian pathogenic escherichia coli strain provided by the invention can be used for preparing avian pathogenic escherichia coli inactivation and attenuated vaccine and bacterial ghost vaccine, and preventing avian pathogenic escherichia coli infection.
Owner:SHANGHAI VETERINARY RES INST CHINESE ACAD OF AGRI SCI
Methionine lyase, as well as encoding gene and biosynthesis method thereof
The invention discloses a methionine lyase, as well as an encoding gene and a biosynthesis method thereof. A gene for encoding the methionine lyase of which the sequence is as shown in SEQ ID No.1 is separated from tuber melanosporum. The invention further provides an efficient biosynthesis method for the methionine lyase. The efficient biosynthesis method comprises the following steps: (1) cloning the gene, of which the sequence is as shown in SEQ ID.1, for encoding the methionine lyase in a yeast expression vector to construct a recombinant yeast expression vector; (2) converting the recombinant yeast expression vector in brewer's yeast to obtain an expression strain; (3) inducing the expression strain to express the methionine lyase, collecting a thallus after induced expression, and purifying the expressed recombinant methionine lyase. The purity of the recombinant methionine lyase prepared according to the biosynthesis method is 90% or higher, and the methionine degrading efficiency can reach 0.53 + / - 0.0030 [mu]M MTL.h<-1>.mg protein<-1>.
Owner:HUBEI UNIV OF TECH
Method for producing selenoneine
ActiveUS20180237815A1High yieldIndustrial-scale productionCarbon-nitrogen lyasesFungiS-Adenosyl methionineSelenocysteine
The purpose of the present invention is to provide a method for producing selenoneine that allows production of selenoneine at higher yields as compared with a conventional technology, and, therefore, enables selenoneine production on an industrial scale. This purpose can be achieved by a method for producing selenoneine, comprising the step of applying histidine and a selenium compound to a transformant that has a gene encoding an enzyme of (1) below introduced therein and that can overexpress the introduced gene, to obtain selenoneine.(1) An enzyme that catalyzes a reaction in which hercynylselenocysteine is produced from histidine and selenocysteine in the presence of S-adenosylmethionine and iron (II).
Owner:KIKKOMAN CORP
Application of genes Gfegt1 and Gfegt2 of ergothioneine of grifola frondosa to synthesis of ergothioneine
The invention discloses application of genes Gfegt1 and Gfegt2 of ergothioneine of grifola frondosa to synthesis of the ergothioneine, and belongs to the field of biosynthetic biology. The possible ergothioneine synthetase genes Gfegt1 and Gfegt2 in the grifola frondosa are found out through a homologous comparison method, and RNA of the grifola frondosa is extracted and then subjected to reversetranscription to generate cDNA for cloning obtaining. Carriers for expression, started by utilizing yeast promoters, of the two genes Gfegt1 and Gfegt2 are constructed, and converted into saccharomyces cerevisiae EC1118, then the saccharomyces cerevisiae is absorbed by adding a substrate, reaction and catalysis are conducted in vivo for synthesizing the ergothioneine, after extracting, generationof ergothioneine products is detected through high performance liquid chromatography (HPLC), in-vivo biosynthesis of the ergothioneine is achieved. A brand new biosynthetic pathway is provided for production of the ergothioneine.
Owner:SOUTH CHINA AGRI UNIV
Isolated enzymatic manufacture of semiconductor nanoparticles
InactiveUS20170335309A1Material nanotechnologyCarbon-sulfur lyasesCell free supernatantSemiconductor Nanoparticles
Novel semiconductor nanoparticles and methods of biosynthesizing the same are provided by biosynthetic processes using cell-free supernatants and isolated enzymes.
Owner:LEHIGH UNIVERSITY
Therapeutic cell systems and methods for treating homocystinuria
InactiveUS20190309271A1Reduced immune reactionLower Level RequirementsCarbon-sulfur lyasesPeptide/protein ingredientsCysteine degradationRed blood cell
The present disclosure relates to erythroid cells that have been engineered to express a homocysteine reducing polypeptide, or a variant thereof, or a homocysteine degrading polypeptide, or a variant thereof. The engineered erythroid cells may further comprise an amino acid transporter, for example a homocysteine transporter or a serine transporter, or a cystathionine degrading polypeptide. The engineered erythroid cells of the present disclosure are useful in reducing the level of homocysteine in a subject. The engineered erythroid cells of the present disclosure are further useful in methods of treating homocystinuria.
Owner:RUBIUS THERAPEUTICS
Methionine metabolites predict aggressive cancer progression
InactiveUS20150204882A1Increase probabilityImmobilised enzymesBioreactor/fermenter combinationsMetaboliteProper treatment
Owner:CEDARS SINAI MEDICAL CENT
Olivol synthase variants and engineered microorganisms expressing them
The present invention provides an olivetol synthase variant and an engineered microorganism expressing it for the production of olivetol and olivetolic acid, more specifically an engineered Escherichia coli, wherein the engineered Escherichia coli is modified to express olive The alcohol synthase variant is characterized in that the olive alcohol synthase variant comprises one or more mutations selected from the following mutations compared with its wild type: I303T, I52L, S56A, H262M and K263R. The engineered E. coli achieves improved yields of olivetol and olivetolic acid.
Owner:BLUEPHA CO LTD +1
Application of attenuated salmonella typhimurium genetic engineering bacterium in preparation of drug for treating liver cancer
ActiveCN106474489AGood antitumor activityMeet the needs of useBacterial antigen ingredientsCarbon-sulfur lyasesGenetic engineeringOrganism
The invention discloses an application of an attenuated salmonella typhimurium genetic engineering bacterium in preparation of a drug for treating liver cancer; the bacterium is attenuated salmonella typhimurium VNP20009 cloned with an L-methioninase gene; the attenuated salmonella typhimurium with a plasmid cloned with the L-methioninase gene can continuously express L-methioninase in a liver cancer tumor tissue, a lot of methionine and other nutrient substances are consumed, and tumor cells are lack of nutrition and grow slow. The invention also discloses a construction method and an application of the genetic engineering bacterium. A biological drug for treating liver cancer is a novel safe and toxic-free biological drug having antitumor activity, takes the attenuated salmonella typhimurium VNP20009 as a vector, highly expresses the methioninase by a gene recombination technology, has strong anti-liver cancer tumor activity, and can meet the use demand. The preparation method is simple and easy to operate, and has a good application prospect.
Owner:GUANGZHOU SINOGEN PHARMA CO LTD
Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria
ActiveUS20180326025A1Reduce homocysteine levelEfficient degradationOrganic active ingredientsCarbon-sulfur lyasesAmino acid substitutionHyperhomocysteinemia
Methods and compositions relating to the engineering of an improved protein with homocyst(e)inase enzyme activity are described. For example, there are disclosed modified cystathionine-γ-lyase (CGL) enzymes comprising one or more amino acid substitutions and capable of degrading homocyst(e)ine. Furthermore, provided are compositions and methods for the treatment of homocystinuria or hyperhomocysteinemia with homocyst(e)ine depletion using the disclosed enzymes or nucleic acids.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Method for preparing allinase, allicin and garlic polysaccharide from garlic slice processing wastewater
ActiveCN107177579AMake full use ofSolve pollutionOrganic chemistryCarbon-sulfur lyasesFiltration membraneDistillation
The invention discloses a method for preparing allinase, allicin and garlic polysaccharide from garlic slice processing wastewater. The method includes steps: (1) after pre-cooling of the garlic slice processing wastewater, adopting an ultra-filtration membrane being 10,000Da in molecular weight cut-off to realize ultra-filtration condensation, and combining cut-off liquid to obtain allinase crude fluid; (2) subjecting ultra-filtration filtrate to nano-filtration condensation through a 300Da nano-filtration membrane, extracting nano-filtration concentrate with CH2Cl2 for multiple times, keeping raffinate for preparation of garlic polysaccharide at the next step, combining CH2Cl2 extraction liquid, and removing CH2Cl2 by reduced pressure distillation to obtain oily liquid mainly composed of allicin; (3) collecting CH2Cl2 raffinate obtained at the step (2), and performing spray drying after reduced pressure distillation to obtain garlic polysaccharide extract. According to the method, respective extraction of various biological active components in the garlic slice processing wastewater is realized, three valuable products are acquired, recycling of the garlic slice processing wastewater is realized, and problems of resource waste and environment pollution in a garlic slice processing process are solved.
Owner:WUXI HONGRUI BIOMEDICAL TECH CO LTD
Method for producing heterocannabinoid phenol by using saccharomyces cerevisiae
ActiveCN112795495AIncrease added valueThe method is accurate and efficientFungiCarbon-sulfur lyasesHeterologousPhenol
The invention discloses a recombinant host cell capable of biosynthesizing cannabinoid phenolic acid, a construction method of the recombinant host cell and a method for biosynthesizing the cannabinoid phenolic acid through the recombinant host cell, and belongs to the field of biotechnology and medicine. The saccharomyces cerevisiae is used as a host, firstly, cannabinoid synthase and cannabinoid phenolic acid synthase are over-expressed in the host, then a metabolic pathway for synthesizing a precursor compound oleylic acid of cannabinoid phenolic acid by using saccharides is constructed in the host, and a metabolic pathway from caproic acid to oleylic acid is further constructed in the host; finally, an endogenous mevalonic acid pathway of a host and a metabolic pathway of acetyl coenzyme A are optimized, the recombinant saccharomyces cerevisiae capable of biologically synthesizing cannabinoid phenolic acid is obtained, a new pathway for producing cannabinoid phenolic acid with high additional value from a cheap carbon source is provided, the production efficiency is high, the period is short, the cost is low, and large-scale production of cannabinoid phenolic acid is facilitated.
Owner:DALIAN UNIV OF TECH +1
Composition capable of preventing and treating respiratory system diseases like novel coronavirus infection and other diseases
InactiveCN111701015AAchieve long-term storageImprove complianceAntibacterial agentsPowder deliveryEscherichia coliStaphylococcus aureus
Owner:WUXI HONGRUI BIOMEDICAL TECH CO LTD
Cannabinoid Production by Synthetic In Vivo Means
In some aspects of the design, novel forms of geranylpyrophosphate:olivetolate geranyltransferase; of olivetol synthase or of geranyl pyrophosphate synthase; of geranylgeranyl pyrophosphate synthase; of olivetolic acid cyclase; and / or of olivetolic acid synthase for making large scale amounts of cannabinoids in cells, in vitro are presented.
Owner:BIOTIC SCI INC
Application of genetically engineered bacterium VNP20009-M to preparation of medicine for treating sarcomas
PendingCN107115533AEfficient killingNo obvious side effectsCarbon-sulfur lyasesBacteriaSide effectWilms' tumor
The invention belongs to the technical field of genetically engineered drugs and particularly relates to new application of a genetically engineered bacterium VNP20009-M to preparation of a medicine for treating sarcomas. On the current basis, the genetically engineered bacterium VNP20009-M is used for treating the sarcomas, can effectively kill tumor cells to eliminate tumor lesions, and the genetically engineered bacterium has no obvious toxic or side effects on a human body, and therefore, provides a safe and effective new way for treating the sarcomas.
Owner:GUANGZHOU SINOGEN PHARMA CO LTD
Recombinant production systems for prenylated polyketides of the cannabinoid family
The present invention relates generally to production methods, enzymes and recombinant yeast strains for the biosynthesis of clinically important prenylated polyketides of the cannabinoid family. Using readily available starting materials, heterologous enzymes are used to direct cannabinoid biosynthesis in yeast.
Owner:BAYMEDICA INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com